Incidence of Hypertension Among US Hispanics/Latinos: The Hispanic Community Health Study/Study of Latinos, 2008 to 2017.

Background Among US Hispanics/Latinos, the largest ethnic minority population in the United States, hypertension incidence has not been thoroughly reported. The goal of this study was to describe the incidence of hypertension among US Hispanic/Latino men and women of diverse Hispanic/Latino background. Methods and Results We studied 6171 participants of the Hispanic Community Health Study/Study of Latinos, a diverse group of self-identified Hispanics/Latinos from 4 US urban communities, aged 18 to 74 years, and free from hypertension in 2008 to 2011 and re-examined in 2014 to 2017. Hypertension was defined as self-reported use of anti-hypertension medication, or measured systolic blood pressure ≥130 mm Hg, or diastolic blood pressure ≥80 mm Hg. Results were weighted given the complex survey design to reflect the target population. Among men, the 6-year age-adjusted probability of developing hypertension was 21.7% (95% CI, 19.5-24.1) and differed by Hispanic/Latino background. Specifically, the probability was significantly higher among men of Cuban (27.1%; 95% CI, 20.2-35.2) and Dominican (28.1%; 95% CI, 19.5-38.8) backgrounds compared with Mexican Americans (17.6%; 95% CI: 14.5-21.2). Among women, the 6-year age-adjusted probability of developing hypertension was 19.7% (95% CI, 18.1-21.5) and also differed by Hispanic/Latino background. Specifically, the probability was significantly higher among women of Cuban (22.6%; 95% CI, 18.3-27.5), Dominican (23.3%; 95% CI, 18.0-29.5), and Puerto Rican (28.2%; 95% CI, 22.7-34.4) backgrounds compared with Mexican Americans (16.0%; 95% CI, 13.9-18.4). Conclusions Hypertension incidence varies by Hispanic/Latino background, with highest incidence among those of Caribbean background.

American College of Cardiology/American Heart Association

alternative healthy eating index

body mass index

blood pressure

cardiovascular disease

diastolic blood pressure

Hispanic Community Health Survey/Study of Latinos

incidence rate

incidence rate ratio

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure

systolic blood pressure

Clinical Perspective

What Is New?

Over 6 years, roughly 1 in 5 US Hispanics/Latinos of the Hispanic Community Health Study/Study of Latinos developed hypertension according to the American College of Cardiology/American Heart Association guidelines, with rates of incident hypertension substantially higher among Hispanics/Latinos of Caribbean background.

Rates of hypertension treatment and control were low across all US Hispanic/Latino background groups.

What Are the Clinical Implications?

Efforts to prevent the development of hypertension and improve rates of hypertension treatment and control among US Hispanics/Latinos require broad‐based public health strategies.

Hypertension is a major contributor to cardiovascular disease (CVD),1 the leading cause of death in the United States. It is associated with shorter overall life expectancy and a shorter duration of living free from CVD.2 In 2017, lower blood pressure (BP) thresholds were introduced to define hypertension.3 In accordance with these guidelines, it is estimated that 46% of US adults now have hypertension, with 36% indicated for hypertension treatment.4

However, among US Hispanics/Latinos, the largest ethnic minority population and also the third‐fastest growing segment of the US population,5 the epidemiology of hypertension has not been adequately described.6 Instead findings have focused on Mexican Americans. For example, the National Health and Nutrition Examination Survey4 and the San Antonio Heart Study7, 8 both show that prevalence or incidence of hypertension among Mexican Americans is comparable or lower than that of non‐Hispanic/Latino whites. However, the broader US Hispanic/Latino population is heterogeneous with respect to background, genetic makeup,9, 10 social composition,11 as well as health‐related behaviors.12, 13 In fact, there is increasing evidence of health differences by Hispanic/Latino background group with a higher prevalence of CVD risk factors, including hypertension, among US Hispanics/Latinos of non‐Mexican versus Mexican background. For instance, cross‐sectional results from the HCHS/SOL (Hispanic Community Health Study/Study of Latinos); showed that the prevalence of hypertension varies considerably across Hispanic/Latino backgrounds with higher prevalence rates among US Hispanics/Latinos from Puerto Rican, Dominican, and Cuban backgrounds and lower rates among US Hispanics/Latinos from Mexican, Central American, and South American backgrounds.14 Yet to date, rates of incident hypertension among diverse US Hispanics/Latinos have not been thoroughly described.

The goals of this study are 2‐fold. First, we aim to estimate incidence rates of hypertension across diverse Hispanic/Latino backgrounds. Second, we aim to estimate the proportion of the HCHS/SOL cohort recommended for hypertension treatment, and who are treated and controlled, according to the 2017 American College of Cardiology/American Heart Association (ACC/AHA) guideline for the prevention, detection, evaluation, and management of high BP in adults.3 To do so, we will leverage longitudinal data from the HCHS/SOL study.

Methods

The data, analytic methods, and study materials can be been made available to other researchers who apply to the HCHS/SOL Publications Committee for purposes of reproducing the results or replicating the procedure.

Study Population

The HCHS/SOL is an ongoing prospective population based cohort study of 16  415 community dwelling, self‐identified Hispanics/Latinos.15, 16 Participants aged 18 to 74 years were recruited in areas surrounding 4 field sites selected because of high populations of Hispanic backgrounds: Bronx, NY; Chicago, IL; Miami‐Dade, FL; and San Diego, CA. A 2‐stage area probability sample of households was selected; stratification and over‐sampling at each stage were used to obtain a diverse and representative sample.15 The baseline visit occurred between 2008 and 2011 and consisted of a standardized examination. A second standardized examination occurred roughly 6 years later between 2014 and 2017. In brief, during the visits, participants underwent laboratory tests and procedures and answered a series of surveys pertaining to their medical history and health behaviors. Informed consent and IRB approval were obtained.

Measurement of Medication and Blood Pressure

During both examinations, participants were asked to self‐report all current medications, including medications for BP, which were recorded by study staff. Following a 5‐minute rest period, BP was measured on the right arm using a cuff which was sized to the upper right arm circumference. Using an OMRON HEM‐907 XL (Omron Healthcare, Inc., Lake Forest, IL)17 automated sphygmomanometer, a trained technician took 3 BP measurements spaced 1 minute apart from seated participants. These 3 measurements were then averaged.

Definition of Hypertension

We considered 2 definitions of hypertension: hypertension according to the updated ACC/AHA guidelines (our primary definition) and for a supplementary analysis (described below), hypertension as defined by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC7),18 which was contemporaneous with the first HCHS/SOL examination (2008–2011) and for most of the second HCHS/SOL examination (2014–2017). Hypertension as per the ACC/AHA guidelines (our primary measure) was defined by meeting any of the following conditions: self‐reported use of hypertension medication, average measured systolic BP (SBP) ≥130 mm Hg, or average diastolic BP (DBP) ≥80 mm Hg.3 Hypertension as per the JNC7 guideline (used in supplementary analysis) was defined by meeting any of the following conditions: self‐reported use of hypertension medication, average measured SBP ≥140 mm Hg, or average DBP ≥90 mm Hg.18 Going forward, all analyses refer to our primary measure (ACC/AHA defined hypertension), unless otherwise stated.

Recommendation for Hypertension Treatment, Hypertension Treatment, and Control

Recommendation for Hypertension Treatment

As per the 2017 ACC/AHA hypertension guideline,3 age, presence of diabetes mellitus, chronic kidney disease (CKD), prior CVD, or ≥10% 10‐year risk of a first hard CVD event (all defined in the covariates section below) were used to define recommendation for hypertension treatment. Recommendation for hypertension treatment was defined as: SBP ≥130 mm Hg for individuals aged ≥65 years, with diabetes mellitus, CKD, a history of CVD, a ≥10% 10‐year risk of a first hard CVD event, or as a DBP ≥80 mm Hg for individuals with diabetes mellitus, CKD, a history of CVD, or a ≥10% 10‐year risk of a first hard CVD event.3 For the general population, recommendation for hypertension treatment was defined by SBP ≥140 mm Hg or DBP ≥90 mm Hg.3 Hypertension treatment was defined as being treated for hypertension (based on self‐reported medication use), among individuals recommended for treatment of hypertension.3 Hypertension control was defined as SBP <130 mm Hg and DBP <80 mm Hg, among individuals recommended for treatment of hypertension.3

Measurement of Other Variables

Variables Measured at the First Examination

Participants were asked to state their country of birth and select a category that best described their Hispanic/Latino background, based on the following response options: Central American, Cuban, Dominican, Mexican, Puerto‐Rican, South American, >1 group, or other. All study participants also reported their age, sex, educational attainment (participants reported their nativity and were classified as US born (excluding the island of Puerto Rico) or non‐US born (including the island of Puerto Rico). Participants who were identified as non‐US born further reported the duration that they had lived in the United States. Nativity/years in the United States was classified as: non‐US born with <10 years in the United States, non‐US born with ≥10 years in the United States, or US born.19 Body mass index (BMI) in kg/m2 was derived from measured weight and height wearing light clothing.16 Elevated SBP (at baseline) was defined as having an average SBP between 120 and 129 mm Hg without meeting the definition for hypertension (defined above). Participants were also queried about their smoking status (never, current, or former smokers) and physical activity was self‐reported using the modified version of the World Health Organization Global Physical Activity Questionnaire and grouped into meeting or not meeting 2008 recommendations.20 Described elsewhere,21 the Alternative Healthy Eating Index‐2010 (AHEI‐2010, range from 0 to 110) was used to assess overall diet.

Variables Measured at the Second Examination

To identify individuals recommended for treatment of hypertension (described above), the following variables were measured at the second examination: age, diabetes mellitus, CKD, prior CVD, and 10‐year risk of first CVD event. Diabetes mellitus/impaired glucose classification was measured from self‐reported medication use, an oral glucose tolerance test, or fasting blood samples and defined as: fasting plasma glucose ≥126 mg/dL, an oral glucose tolerance test 2‐hour post‐load glucose level ≥200 mg/dL, glycated hemoglobin ≥6.5%, or self‐reported use of hypoglycemic agents.22 CKD was defined as having an estimated glomerular filtration rate <60 mL/min per 1.73 m2.23 Age at examination 2 was self‐reported along with history of CVD (defined as prior heart attack, stroke, or heart procedure such as: angioplasty, stent, or bypass). Among individuals without a history of CVD, 10‐year predicted risk of CVD was calculated using the pooled cohort risk equations.24

Analytical Sample

For our primary analyses, of the 16 415 HCHS/SOL participants recruited from 2008 to 2011, we excluded individuals: with hypertension (n=5300) or missing hypertension information (n=66) at examination 1, and those who did not show up (n=4792) or were missing hypertension information (n=86) at examination 2. Our final analytic sample included 6171 participants. For our supplementary analysis using JNC7 to define hypertension our analytic sample size was larger and included n=7730 participants free from JNC7 defined hypertension at examination 1 and with complete information. Individuals who participated in both visits versus only the first visit, were older (43.1 versus 37.3 years old, P<0.01), more likely to be female (56.2% versus 44.6%, P<0.01), had higher mean BMI (29.5 versus 29.1 kg/m2, P=0.04), higher SBP (120.3 versus 119.3 mm Hg, P=0.02) but did not differ based on DBP (72.4 versus 71.8 mm Hg, P=0.60) during the first examination.

Statistical Analysis

All analyses accounted for the complex survey design including cluster sampling and the use of stratification in sample selection. The sampling weights were calculated based on the baseline sampling weights and accounted for the non‐responses for examination 2. The sampling weights are trimmed, calibrated to the age, sex, and Hispanic/Latino background distributions from the 2010 US Census for the 4 study field centers based on participants’ age at the first examination, and normalized.

Among the population free from hypertension, we first described baseline demographic, socioeconomic, clinical, and behavioral characteristics. We calculated mean follow‐up time beginning at the date of each participant's first study visit (baseline examination) and ending at the date of the second study visit (follow‐up examination). Using Poisson regression through generalized linear regression models, we estimated incidence rates (IRs) of hypertension, per 1000 person‐years (PY), as well as incidence rate ratios (IRRs) overall and according to baseline demographic, socioeconomic, clinical, and behavioral factors of interest. Except for the estimates reported across age groups, all IRs and IRRs were age adjusted to the overall HCHS/SOL baseline age distribution. We also estimated IRRs fully adjusted for: age, Hispanic/Latino background, education, income, nativity/years in the United States, health insurance, BMI, elevated SBP, smoking, physical activity, and AHEI 2010.

Additionally, for each Hispanic/Latino background group, we reported the 6‐year age‐adjusted predicted probability of developing hypertension. Next, we estimated the percentage of individuals recommended for treatment of hypertension (in the whole population and restricted to individuals with hypertension). Among individuals recommended for treatment of hypertension, we estimated the proportion treated and the proportion controlled. Finally, as a supplementary analysis, we also presented age standardized cumulative incidences along with age‐adjusted IRs, and IRRs according to the JNC7 definition of hypertension. All results were stratified by sex. Analyses were conducted in SUDAAN (Version 11.0.1, Research Triangle Institute, NC) to account for the complex survey design and the sampling weights.

Results

Baseline demographic and socioeconomic characteristics of the overall US Hispanics/Latinos free from hypertension in the HCHS/SOL target population in 2008 to 2011 (displayed in Table 1) were similar between men and women with 7.8% (95% CI, 6.4–9.4) in Central American, 15.3% (95% CI, 12.7–18.3) in Cuban, 9.1% (95% CI, 7.6–10.7) in Dominican, 44.2% (95% CI, 40.7–47.7) in Mexican, 13.4% (95% CI, 11.8–15.2) in Puerto Rican, and 5.4% (95% CI, 4.5–6.5) in South American background groups. The overall study population was mostly young with 53.6% (95% CI, 51.6–55.5) aged 18 to 34 years, 31.9% (95% CI, 30.2–33.7) aged 35 to 49 years, 12.3% (95% CI, 11.4–13.3) aged 50 to 64 years, and 2.2% (95% CI, 1.7–2.8) aged 65 to 74 years. Overall, 29.0% (95% CI, 27.1–31.0) had less than a high school education, with 59.9% (95% CI, 57.7–62.0) having an income <$30 000 per year, 27.7% (95% CI, 25.7–29.7) born in the United States, and 46.3% (95% CI, 43.9–48.5) with health insurance. Compared with men, at baseline, women were more likely to have the following: lower income, health insurance, obesity, and lower (less favorable) AHEI 2010 scores. Women were less likely to: be US born, have elevated SBP, smoke, or meet physical activity guidelines compared with men (P values all <0.05).

Table 1

Baseline Characteristics of Individuals Free From Hypertension in the HCHS/SOL Target Population by Sex, 2008 to 2011

	Overall (Unweighted N=6171)			Men (Unweighted n=2137)			Women (Unweighted n=4034)
	Unweighted	Weighted		Unweighted	Weighted		Unweighted	Weighted
	n	%	95% CI	n	%	95% CI	n	%	95% CI
Hispanic/Latino backgrounda
Mexican	3031	44.2	40.7–47.7	1001	41.8	37.8–46.0	2030	46.1	42.3–49.9
Central American	659	7.8	6.4–9.4	209	7.6	5.9–9.9	450	7.9	6.5–9.5
Cuban	636	15.3	12.7–18.3	262	16.7	13.6–20.3	374	14.2	11.6–17.3
Dominican	452	9.1	7.6–10.7	122	7.5	5.7–9.8	330	10.3	8.7–12.3
Puer– Rican	726	13.4	11.8–15.2	288	15.3	13.0–17.8	438	11.8	10.1–13.8
South American	483	5.4	4.5–6.5	177	5.5	4.3–6.9	306	5.4	4.4–6.5
Mixed/other	173	4.9	4.0–6.0	73	5.6	4.1–7.5	100	4.3	3.3–5.6
Women	4034	54.3	52.5–56.1
Age group
18–34 y	1825	53.6	51.6–55.5	691	54.5	51.3–57.6	1134	52.8	50.6–55.0
35–49 y	2490	31.9	30.2–33.7	806	31.4	28.6–34.4	1684	32.3	30.5–34.3
50–64 y	1703	12.3	11.4–13.3	580	11.8	10.5–13.3	1123	12.7	11.7–13.9
65–74 y	153	2.2	1.7–2.8	60	2.3	1.5–3.5	93	2.1	1.5–2.8
Less than HS education	2093	29.0	27.1–31.0	728	29.7	27.0–32.5	1365	28.4	26.1–30.8
Income <$30 000a	3880	59.8	57.7–62.0	1228	54.6	51.4–57.8	2652	64.2	61.9–66.5
Nativity/years in the United Statesa
Non‐US born <10 y in United States	1591	30.7	28.4–33.1	503	28.5	25.5–31.8	1088	32.5	29.8–35.3
Non‐US born, ≥10 y in United States	3391	41.6	39.7–43.6	1172	41.4	38.6–44.2	2219	41.8	39.6–44.1
US born	1169	27.7	25.7–29.7	455	30.1	27.2–33.1	714	25.7	23.4–28.1
Health insureda	2768	46.2	43.9–48.5	902	44.2	41.0–47.4	1866	47.9	45.3–50.4
Body mass indexa
Normal	1590	30.5	28.7–32.4	553	30.4	27.6–33.3	1037	30.6	28.4–32.9
Overweight	2402	37.0	35.3–38.8	930	40.2	37.4–43.1	1472	34.4	32.3–36.5
Obese	2170	32.5	30.6–34.4	563	29.4	26.6–32.4	1517	35.0	32.7–37.4
Elevated SBPa (120–129 mm Hg)	1330	20.1	18.7–21.6	698	30.8	28.2–33.5	632	11.0	9.9–12.3
Smokinga
Never	3984	66.4	64.6–68.1	1097	57.3	54.3–60.3	2887	73.9	71.7–75.9
Current	1136	20.2	18.6–21.8	530	25.4	22.8–28.3	606	15.8	14.2–17.6
Former	1033	13.5	12.4–14.6	498	17.2	15.3–19.4	535	10.3	9.1–11.7
Meets 2008 PA guidelinesa	4059	71.1	69.3–72.8	1651	80.7	78.4–82.9	2408	63.0	60.7–65.2
AHEI 2010, meana		47.0	46.6–47.4		48.4	47.9–48.9		45.8	45.4–46.3

Except for age‐specific estimates, all estimates are age standardized to the overall baseline age distribution. AHEI indicates alternative healthy eating index; HCHS/SOL, Hispanic Community Health Study/Study of Latinos; HS, high school; PA, physical activity; PY, person‐years; and SBP, systolic blood pressure.

Indicates that estimates are differ significant (P<0.05) according to sex using Chi‐squares for proportions and t tests for means.

The mean follow‐up time between each examination was 6.2 years (95% CI, 6.1–6.2) with an overall age adjusted IR of 34 per 1000 PY (95% CI, 31–36). Among men, the overall age adjusted IR of hypertension was 36 per 1000 PY (95% CI, 32–40), though it differed by Hispanic/Latino background group, P=0.04 (Table 2). For example, hypertension IRs were 58% higher (IRR, 1.58; 95% CI, 1.19–2.10) among men of Cuban background (IR, 45 per 1000 PY; 95% CI, 37–56) and 61% higher (IRR, 1.61; 95% CI, 1.03–2.52) among men of Dominican background (IR, 46 per 1000 PY; 95% CI, 31–70) compared with Mexican American men (IR, 29 per 1000 PR; 95% CI, 24–35). Additionally, among men, IRs were higher with older age, greater education, higher BMI, and elevated BP, and lower with a higher (more favorable) AHEI score. From fully adjusted models, hypertension IRRs remained higher among men of Cuban (IRR, 1.66; 95% CI, 1.08–2.53) and Dominican (IRR, 1.69; 95% CI, 1.07–2.68) background compared with Mexican American men.

Table 2

Incidence of Hypertension Among US Hispanic/Latino Men in the HCHS/SOL Target Population by Baseline Characteristics

	Incidence Rate (Per 1000 PY)		Incidence Rate Ratio		Fully Adjusteda Incidence Rate Ratio
	IR	95% CI	IRR	95% CI	IRR	95% CI
Overall	35	32–39	···		···
Hispanic/Latino background
Mexican (ref)	29	24–35	1.00	···	1.00	···
Central American	32	22–46	1.10	0.72–1.70	1.20	0.78–1.85
Cuban	45b	37–56	1.58	1.19–2.10	1.66b	1.08–2.53
Dominican	46	31–70	1.61	1.03–2.52	1.69b	1.07–2.68
Puer– Rican	35	27–45	1.22	0.90–1.66	1.29	0.85–1.94
South American	30	20–45	1.04	0.66–1.63	1.12	0.69–1.81
Mixed/other	42	25–70	1.47	0.85–2.53	1.48	0.86–2.57
Age group
18–34 y (ref)	21	26–26	1.00	···	1.00	···
35–49 y	45b	39–52	2.19	1.65–2.92	1.99b	1.44–2.75
50–64 y	67b	59–76	3.25	2.47–4.27	2.82b	1.98–4.00
65–74 y	85b	56–128	4.13	2.56–6.68	3.59b	2.12–6.08
Education
HS or more (ref)	37	33–43	1.00	···	1.00	···
Less than HS	30b	25–35	0.80b	0.64–0.99	0.77b	0.61–0.96
Income
≥$30 000 (ref)	33	27–40	1.00	···	1.00	···
<$30 000	37	32–42	1.12	0.88–1.42	1.08	0.85–1.36
Nativity/y in the United States
Non‐US born <10 y in United States (ref)	33	27–41	1.00	···	1.00	···
Non‐US born, ≥10 y in United States	36	31–41	1.07	0.84–1.36	1.21	0.96–1.54
US born	34	27–43	1.03	0.75–1.40	1.09	0.78–1.53
Health insurance
Yes (ref)	34	28–40	1.00	···	1.00	···
No	37	28–40	1.09	0.88–1.35	1.06	0.85–1.31
Body mass index
Normal (ref)	25	20–31	1.00	···	1.00	···
Overweight	34b	29–40	1.37	1.05–1.78	1.43b	1.09–1.88
Obese	47b	39–56	1.90	1.44–2.52	1.95b	1.47–2.58
Systolic BP
<120 mm Hg (ref)	28	24–32	1.00	···	1.00	···
120–129 mm Hg	51b	44–59	1.85b	1.52–2.26	1.87b	1.53–2.27
Smoking
Never (ref)	33	28–39	1.00	···	1.00	···
Current	38	31–46	1.34	0.89–1.45	1.24	0.98–1.58
Former	35	28–43	1.05	0.82–1.35	1.11	0.88–1.41
Meets 2008 PA guidelines
Yes (ref)	32	26–40	1.00	···	1.00	···
No	36	32–41	0.90	0.70–1.15	0.89	0.70–1.13
AHEI 2010‡	36	32–40	0.88b	0.80–0.97	0.97	0.85–1.11

Except for age specific estimates, all IRs and IRRs are age adjusted. AHEI indicates alternative healthy eating index; HCHS/SOL, Hispanic Community Health Study/Study of Latinos; HS, high school; IR, incidence rate; IRR, incidence rate ratio; PA, physical activity; PY, person‐years; and SBP, systolic blood pressure.

Fully adjusted for all covariates in the table.

Estimate is significantly different from the reference category, P<0.05.

IR estimated at a mean value of AHEI 2010 (47 units); IRR estimates reflect 1 SD (7.6 units).

Among women, the overall age adjusted IR of hypertension was 32 per 1000 PY (95% CI, 30–35), though it differed by Hispanic/Latino background group, P<0.01 (Table 3). For example, hypertension IRs were 46% higher (IRR, 1.46; 95% CI, 1.16–1.83) among women of Cuban background (IR, 38 per 1000 PY; 95% CI, 32–46), 48% higher (IRR, 1.48; 95% CI, 1.08–2.04) among women of Dominican background (IR, 39 per 1000 PY; 95% CI, 29–51), and 71% higher (IRR, 1.71; 95% CI, 1.34–2.19) among women of Puerto Rican background (IR, 45 per 1000 PY; 95% CI, 37–55) compared with Mexican American women (IR, 26 per 1000 PR; 95% CI, 23–30). Additionally, among women, IRs were higher with older age, less education, lower income, health insurance, higher BMI, elevated BP, current smoking, and lower with a higher (more favorable) AHEI score. From fully adjusted models, hypertension IRRs attenuated such that IRRs were no longer higher among women of Cuban (IRR, 1.32; 95% CI, 0.98–1.77), Dominican (IRR, 1.38; 95% CI, 0.99–1.93), or Puerto Rican (IRR, 1.16; 95% CI, 0.87–1.56) background compared with Mexican American women.

Table 3

Incidence of Hypertension Among US Hispanic/Latino Women in the HCHS/SOL Target Population by Baseline Characteristics

	Incidence Rate (Per 1000 PY)		Incidence Rate Ratio		Fully Adjusteda Incidence Rate Ratio
	IR	95% CI	IRR	95% CI	IRR	95% CI
Overall	32	30–35	···		···
Hispanic/Latino background
Mexican (ref)	26	23–30	1.00	···	1.00	···
Central American	31	32–46	1.20	0.91–1.57	1.13	0.85–1.51
Cuban	38b	32–46	1.46b	1.16–1.83	1.32	0.98–1.77
Dominican	39b	29–51	1.48b	1.08–2.04	1.38	0.99–1.93
Puer– Rican	45b	37–55	1.71b	1.34–2.19	1.16	0.87–1.56
South American	26	19–36	1.01	0.71–1.43	1.08	0.75–1.55
Mixed/other	47	28–77	1.79b	1.07–2.99	1.53	0.92–2.53
Age group
18–34 y (ref)	18	15–23	1.00	···	1.00	···
35–49 y	38b	33–43	2.07b	1.60–2.67	1.85b	1.42–2.42
50–64 y	63b	57–70	3.47b	2.76–4.36	2.49b	1.90–3.25
65–74 y	120b	100–144	6.58b	4.93–8.77	4.03b	2.76–5.89
Education
HS or more (ref)	30	27–33	1.00	···	1.00	···
Less than HS	38b	33–44	1.27b	1.09–1.50	1.25b	1.05–1.48
Income
≥$30 000 (ref)	28	23–33	1.00	···	1.00	···
<$30 000	35b	32–39	1.28b	1.04–1.57	1.19	0.97–1.45
Nativity/years in the United States
Non‐US born <10 y in United States (ref)	30	26–35	1.00	···	1.00	···
Non‐US born, ≥10 y in United States	32	28–36	1.05	0.87–1.28	0.99	0.80–1.22
US born	37	30–46	1.23	0.94–1.60	1.02	0.74–1.40
Health insurance
Yes (ref)	38	24–31	1.00	···	1.00	···
No	28b	33–42	0.73b	0.62–0.88	0.76b	0.62–0.92
Body mass index
Normal (ref)	21	17–26	1.00	···	1.00	···
Overweight	31b	27–36	1.50b	1.14–1.97	1.39b	1.06–1.81
Obese	42b	37–48	2.02b	1.57–2.60	1.81b	1.42–2.31
Systolic BP
<120 mm Hg (ref)	27	24–30	1.00	···	1.00	···
120–129 mm Hg	63b	54–72	2.32b	1.95–2.76	2.19b	1.83–2.62
Smoking
Never (ref)	30	27–34	1.00	···	1.00	···
Current	41b	34–49	1.35b	1.10–1.65	1.29b	1.03–1.61
Former	34	27–44	1.13	0.87–1.48	1.11	0.88–1.41
Meets 2008 PA guidelines
Yes (ref)	32	29–36	1.00	···	1.00	···
No	34	29–36	1.05	0.89–1.25	1.05	0.89–1.23
AHEI 2010c	33	30–36	0.83b	0.77–0.90	0.94	0.83–1.06

Except for age specific estimates, all IRs and IRRs are age adjusted. AHEI indicates alternative healthy eating index; HCHS/SOL, Hispanic Community Health Study/Study of Latinos; HS, high school; IR, incidence rate; IRR, incidence rate ratio; PA, physical activity; PY, person‐years; and SBP, systolic blood pressure.

Fully adjusted for all covariates in the table.

Estimate is significantly different from the reference category, P<0.05.

IR estimated at a mean value of AHEI 2010 (47 units); IRR estimates reflect 1 SD (7.6 units).

Among individuals free from hypertension at baseline, ≈1 in 5 developed hypertension 6 years later (20.6%; 95% CI, 19.2–22.1), see Figure which depicts the 6‐year age‐adjusted probability of developing hypertension by sex and Hispanic/Latino background group. Also, among all individuals free from hypertension at baseline, the prevalence of hypertension treatment recommendation was 14.4% for men (95% CI, 12.8–16.1) and 11.9% for women (95% CI, 10.7–13.3), Table 4. When restricted to individuals with incident hypertension, the prevalence of hypertension treatment recommendation was 56.7% for men (95% CI, 49.6–63.5) and 51.5% for women (95% CI, 44.9–58.1). Among individuals recommended for hypertension treatment, the prevalence of hypertension treatment was 30.9% among men (95% CI, 23.6–39.2) and 37.4% among women (95% CI, 30.3–45.0). Also, among individuals recommended for hypertension treatment, the prevalence of hypertension control was 18.4% among men (95% CI, 12.8–25.9) and 22.7% among women (95% CI, 17.1–29.5). The prevalence of hypertension treatment recommendation, treatment, and control by Hispanic/Latino background group are also presented in Table 4.

Figure 1

Age‐adjusted predicted probability of developing of hypertension over 6 years among US Hispanic/Latino men and women, Hispanic Community Health Study/Study of Latinos, 2008 to 2017.

Predicted probability of developing hypertension differs among US Hispanic/Latino women (P<0.05); men (P=0.11). *Predicted probability of developing hypertension is significantly greater than Mexican Americans, P<0.05.

Table 4

Prevalence of US Hispanics/Latinos Recommended for Hypertension Treatment, Treated, and Controlled in the HCHS/SOL Target Population by Sex

	Men				Women
	Recommended for Treatment		Treated	Controlled	Recommended for Treatment		Treated	Controlled
	(Among All Men)	(Among All Men With Hypertensiona)	(Among All Men Recommended for Hypertension Treatmentb)		(Among All Women)	(Among All Women With Hypertensiona)	(Among All Women Recommended For Hypertension Treatmentb)
	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
Overall	14.4 (12.8–16.1)	56.7 (49.6–63.5)	26.6 (19.9–34.5)	18.4 (12.8–25.9)	11.9 (10.7–13.3)	51.5 (44.9–58.1)	36.4 (29.6–43.8)	22.7 (17.1–29.5)
Hispanic/Latino background
Mexican (reference)	12.5 (10.2–15.3)	63.3 (51.7–73.4)	27.7 (18.3–39.5)	20.3 (12.1–31.9)	10.8 (9.2–12.6)	56.8 (47.0–66.2)	49.8 (36.2–63.4)	33.5 (22.0–47.4)
Central American	13.3 (9.6–18.0)	47.1 (31.4–63.5)	15.4 (8.2–27.2)	11.8 (5.5–23.3)	9.6 (7.5–12.2)	41.3 (31.2–52.2)c	30.0 (18.1–45.4)c	19.1 (12.9–27.3)
Cuban	17.4 (12.9–23.2)	55.4 (32.7–76.1)	16.6 (10.5–25.2)	10.6 (5.4–19.8)	12.1 (9.2–15.8)	47.2 (28.4–66.8)	25.5 (17.2–36.1)c	19.0 (11.3–30.2)
Dominican	14.4 (10.2–20.1)	38.1 (22.1–57.2)c	43.4 (13.4–79.2)	36.3 (9.5–75.5)	10.8 (8.2–14.1)	34.2 (25.0–44.9)c	22.8 (14.2–34.4)c	12.5 (5.7–25.3)c
Puerto Rican	14.2 (10.5–18.9)	55.5 (39.3–70.7)	24.3 (11.1–45.2)	20.4 (8.2–42.3)	18.2 (13.5–24.2)c	63.7 (46.8–77.8)	28.7 (18.7–41.5)c	7.9 (3.3–17.7)c
South American	9.3 (5.8–14.4)	39.6 (23.7–58.1)c	7.8 (3.6–16.0)c	7.5 (3.3–15.8)c	7.5 (5.5–10.0)c	32.0 (24.3–40.9)c	77.4 (63.9–86.9)c	72.9 (60.5–82.6)c
Mixed/other	23.5 (13.7–37.2)	74.3 (48.0–90.1)	27.3 (7.9–62.3)	10.9 (2.6–35.8)	16.3 (8.7–28.4)	58.8 (33.1–80.4)	25.1 (10.4–49.3)c	20.1 (8.4–41.0)

All estimates are age standardized to the overall baseline age distribution (shown in Table 1). HCHS/SOL indicates Hispanic Community Health Study/Study of Latinos.

Among individuals with hypertension (unweighted n=575 for men and n=970 for women).

Among individuals recommended for treatment of hypertension (unweighted n=456 for men and n=669 for women).

Estimate is significantly different from Mexican Americans, the reference category, P<0.05.

The incidence of hypertension according to JNC7 defined guidelines are displayed in Table S1 and show similar results, with higher incidence of hypertension among US Hispanics/Latinos of Caribbean background.

Discussion

In a large cohort of diverse US Hispanics/Latinos free from hypertension in 2008 to 2011, the 6‐year probability of developing hypertension was 21% overall or 22% among men and 20% among women. Hypertension IRs were highest among US Hispanics/Latinos from Caribbean backgrounds (Cuban, Dominican, and Puerto Rican). Among US Hispanics/Latinos without hypertension in 2008 to 2011, 14% of men and 12% of women were recommended for treatment of hypertension 6 years later. Among individuals recommended for treatment of hypertension, the prevalence of treatment was 27% among men and 36% among women; the prevalence of control was 18% among men 23% among women. Thus, our findings demonstrate substantial variation in hypertension incidence by Hispanic/Latino background group and emphasize that rates of hypertension treatment and control among US Hispanics/Latinos are low.

Though most studies classify Hispanics/Latinos as a homogeneous group, US Hispanics/Latinos are diverse with respect to background of origin, race, immigration history, socioeconomic status, and culture.6 This diversity likely manifests in variation in CVD and its risk factors across Hispanic/Latino background groups.14 In fact, results from the Multi‐Ethnic Study of Atherosclerosis first showed a higher prevalence of hypertension among Dominican versus Mexican or Puerto Rican backgrounds.25 Data from the National Health Interview Survey showed a higher prevalence of hypertension among black versus white Hispanics/Latinos.26 Cross‐sectional results from HCHS/SOL, the largest study of Hispanics/Latinos of diverse backgrounds also showed variation in the prevalence of CVD risk factors14, 17—including hypertension, with the highest rates among HCHS/SOL participants of Caribbean backgrounds.17 Our findings, which serve as a longitudinal extension of prior HCHS/SOL cross‐sectional results, are consistent and show higher rates of incident hypertension among US Hispanics/Latino of Cuban, Dominican, and Puerto Rican (women only) compared with Mexican backgrounds.

Reasons underlying the higher rates of hypertension among Hispanics/Latinos of Dominican and Cuban versus Mexican backgrounds warrant additional investigation. It has been noted that a longer duration of US residence is associated with hypertension.19, 27, 28 For example, studies show that Mexican Americans born in the United States have a lower prevalence of hypertension than their Mexican born counterparts.19, 29 However, our findings showed that recent immigration (within 10 years) was not protective against the development of hypertension 6‐years later. As acculturation experience and its relationship to hypertension may differ based on country of origin,6, 28 research related to acculturation may be more informative when conducted within one specific Hispanic/Latino background, rather than in aggregate. It has also been suggested that a higher proportion of African admixture may manifest in higher rates of hypertension25—particularly among Hispanics/Latinos shown to have a greater proportion of African admixture, such as those of Dominican background.9 However, disentangling the role of African admixture from skin color based discrimination,30 or Hispanic/Latino background,9 in the development of hypertension would be challenging. Further, prior work has seldom shown hypertension to be primarily genetically mediated. For example, results from the Family Blood Pressure Program showed that racial differences in blood pressure between whites and blacks may be better explained by education than by genetics.31 While our results accounted for common behavioral contributors to hypertension which may differ across Hispanic/Latino background groups such as: BMI, physical activity, and diet, future studies may focus more closely on other contributing factors. In a recent paper, sodium, potassium, and the ratio of sodium to potassium, all of which are associated with blood pressure,32 and also hypertension control,33 were shown to differ among US Hispanics/Latinos of the HCHS/SOL.34 Whether differences in sodium intake, and salt sensitivity35, 36, 37 across Hispanic/Latino background groups played a role in the noted differences in hypertension incidence is yet to determined.

Trends in incident hypertension also differed by sex. For example, lower educational attainment was associated with lower risk of hypertension among men, but higher risk of hypertension among women. These results are consistent with literature showing strong associations of low socioeconomic factors with poorer health status, among women in particular.38, 39, 40 Additionally, among US Hispanic/Latino women, Puerto Ricans had the highest rate of incident hypertension—71% higher than Mexican Americans. Yet after adjustment for socioeconomic, clinical, and behavioral characteristics, Puerto Rican women fared no different than women of Mexican background. Further, the risk of hypertension among women of Cuban and Dominican versus Mexican background were attenuated in fully adjusted models—a finding which was not reproduced in men. Taken together these data suggest that factors driving hypertension among US Hispanics/Latinos may differ based on sex. Further investigation is necessary to determine which sex‐specific factors drive such differences.

The 2017 ACC/AHA hypertension guideline recommends treatment for hypertension at a higher BP threshold (in the general population) than what is used to define hypertension.3 Therefore, there is a discrepancy between the proportion classified as having hypertension versus those requiring treatment. Among US Hispanics/Latinos who developed hypertension, slightly greater than half were recommended for treatment. Of concern are the particularly low rates of hypertension treatment and control among US Hispanics/Latinos (<40% treated and 23% controlled). While these data may suggest low rates of hypertension awareness among recent cases, they nevertheless emphasize the need for a concerted public health effort to increase the proportion of US Hispanics/Latinos controlled. A lack of health insurance has been routinely linked to poor outcomes41 including uncontrolled hypertension.42 In the current sample, less than half of participants had health insurance at baseline—potentially having important implications related to hypertension management. Further assessment of the impact of insurance status on management of hypertension among US Hispanics/Latinos, particularly after the passage of the Affordable Care Act, may be warranted.

Study Limitations

This work is not without limitations. First, we acknowledge that there was considerable loss to follow‐up in this study resulting in a smaller sample size. However, given the descriptive nature of our findings, it is unlikely that loss to follow‐up influenced study results. Further, due in part to sample size constraints, we were unable to present results for all US Hispanics/Latinos by background country of origin. As a result, US Hispanics/Latinos of South American and Central American backgrounds (not including Mexico) were aggregated, limiting our ability to make more specific conclusions based on country of origin for these groups.

Additionally, the 2017 ACC/AHA guideline for the diagnosis of hypertension requires a measurement of high BP on 2 separate occasions.3 In the current study, incident hypertension was defined by BP measurements ascertained once (at the follow‐up examination). Likewise, hypertension treatment may be subject to some measurement error given that it was assessed via self‐report. Further, we were unable to assess hypertension awareness, as the 2017 ACC/AHA guideline was released in November 2017, 1 month before the completion of the HCHS/SOL follow‐up examination. This is notable given historically low rates of hypertension awareness among US Hispanics/Latinos,43 ranging from 57% among Central American men to 78% among Cuban men and from 72% among South American women to 79% among Cuban and Dominican women.17 Additionally, our measures of hypertension treatment recommendation, hypertension treatment, and BP control were estimated among individuals with new onset hypertension (within 6 years) and therefore do not reflect individuals with prevalent hypertension. For example, rates of hypertension treatment may be more common among older individuals or more established cases of hypertension.44 Further, the proportion with controlled hypertension may be particularly low among those with new onset hypertension as control may be a function of time since diagnosis. Though we note among Mexican Americans sampled in National Health and Nutrition Examination Survey, rates of hypertension treatment, and control have also been historically lower than among non‐Hispanic whites.43 Taken together, these findings suggest, at the least, that an examination of whether a more culturalized approach to primary care may be effective at improving outcomes in this population is warranted.

Despite limitations, this study makes an important contribution to the sparse6 literature related to the development of hypertension among US Hispanics/Latinos. To our knowledge, it is the first study of its kind to report on rates of incidence hypertension among Hispanics/Latinos of diverse backgrounds using the 2017 ACC/AHA guidelines. It includes standardized measurements of BP which were clinically ascertained. Additionally, given the large sample, we were able to describe and compare rates of hypertension not only across Hispanic/Latino background groups, but also by sex. Therefore, this study provides an important first look into the development of hypertension among US Hispanics/Latinos adults and highlights disparities across different Hispanic/Latino background groups.

Conclusions

In summary, among participants of a large population based study of US Hispanics/Latinos of diverse backgrounds, we found substantial variation in rates of incident hypertension. US Hispanics/Latinos from Caribbean backgrounds had the highest rates of hypertension. Disparities could not be fully explained by traditional hypertension risk factors (especially true among men), warranting further investigation. Additionally, rates of hypertension treatment and control among US Hispanics/Latinos were found to be suboptimal. Efforts to improve these indices require broad based public health strategies.

Sources of Funding

The Hispanic Community Health Study/Study of Latinos was performed as a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute to the University of North Carolina (N01‐HC65233), University of Miami (N01‐HC65234), Albert Einstein College of Medicine (N01‐HC65235), Northwestern University (N01‐HC65236), and San Diego State University (N01‐HC65237). Dr Elfassy was supported by the University of Miami Clinical and Translational Science Institute, from National Institutes of Health/National Center for Advancing Translational Sciences (KL2TR002737), she is currently supported by National Institutes of Health/National Institute on Minority Health and Health Disparities (K01MD014158).

Disclosures

None.

Table S1

Click here for additional data file.